Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 17:19:921-928.
doi: 10.2147/NDT.S390482. eCollection 2023.

Prescribing Trends for the Same Patients with Schizophrenia Over 20 Years

Norio Yasui-Furukori  1   2 , Yasushi Kawamata  1   3 , Taro Sasaki  1   4 , Saaya Yokoyama  1   5 , Hiroaki Okayasu  1   6 , Masataka Shinozaki  1   7 , Yoshitaka Takeuchi  1   8 , Aoi Sato  1   9 , Takaaki Ishikawa  1   10 , Hazuki Komahashi-Sasaki  1   11 , Kensuke Miyazaki  12 , Takashi Fukasawa  13 , Hanako Furukori  14 , Norio Sugawara  1   2 , Kazutaka Shimoda  1
Affiliations

Prescribing Trends for the Same Patients with Schizophrenia Over 20 Years

Norio Yasui-Furukori et al. Neuropsychiatr Dis Treat. .

Abstract

Background: Recent pharmacoepidemiology data show an increase in the proportion of patients receiving second-generation antipsychotic (SGA) monotherapy, but no studies have analyzed the same patients over a long period of time. Therefore, in this study, we retrospectively evaluated schizophrenia patients with available data for 20 years to determine whether the drug treatments in the same patients have changed in the past 20 years.

Methods: The study began in April 2021 and was conducted in 15 psychiatric hospitals in Japan. Schizophrenia patients treated in the same hospital for 20 years were retrospectively examined for all prescriptions in 2016, 2011, 2006, and 2001 (ie, every 5 years).

Results: The mean age of the 716 patients surveyed in 2021 was 61.7 years, with 49.0% being female. The rate of antipsychotic monotherapy use showed a slight increasing trend over the past 20 years; the rate of SGA use showed a marked increasing trend from 28.9% to 70.3% over the past 20 years, while the rate of SGA monotherapy use showed a gradual increasing trend over the past 20 years. The rates of concomitant use of anticholinergics, antidepressants, anxiolytics/sleep medications, and mood stabilizers showed decreasing, flat, flat, and flat trends over the past 20 years, respectively.

Conclusion: The results of this study showed a slow but steady substitution of SGAs for first-generation antipsychotics (FGAs) over time, even in the same patients.

Keywords: antipsychotics; pharmacoepidemiology; prescription; schizophrenia; trends.

PubMed Disclaimer

Conflict of interest statement

Dr. Kensuke Miyazaki reports personal fees from Sumitomo Dainippon Pharma Co., Ltd., outside the submitted work. Professor Kazutaka Shimoda reports grants from Novartis Pharma KK, Dainippon Sumitomo Pharma Co., Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., Eisai Co., Ltd., Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Takeda Pharmaceutical Co., Ltd.; personal fees from Eisai Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Janssen Pharmaceutical Co., Shionogi & Co. Ltd., Dainippon Sumitomo Pharma Co., Daiichi Sankyo Co., and Pfizer Inc., outside the submitted work. The remaining authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Left-hand (A): The dotted line shows the trend of the prescribing rate of all antipsychotics over time. Black circles indicate trends in prescription rates for first-generation antipsychotics (FGA). White circles indicate trends in prescribing rates for second-generation antipsychotics (SGA). Right-hand (B): These broken lines show the trend of chlorpromazine equivalent doses of all antipsychotics over time. Black circles indicate trends in chlorpromazine equivalent doses for FGA. White circles indicate trends in chlorpromazine equivalent doses for SGAs.
Figure 2
Figure 2
Correlation between prescription rates of anticholinergics and antipsychotics. Black circles indicate trends in prescription rates for first-generation antipsychotics (FGA). White circles indicate trends in prescribing rates for second-generation antipsychotics (SGA).
See this image and copyright information in PMC

References

    1. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71–93. doi: 10.1093/schbul/sbp116 - DOI - PMC - PubMed
    1. Hasan A, Wobrock T, Gaebel W, et al. Germany Society of Psychotherapy and Psychosomatics (DGPPN); German Association of Psychiatry. Nervenarzt. 2013;84:1359–60, 1362–4, 1366–8. doi: 10.1007/s00115-013-3913-6 - DOI - PubMed
    1. NICE. Psychosis and Schizophrenia in Adults: The NICE Guideline on Treatment and Management. NICE Clinical Guideline 178; 2014. Available from: https://www.nice.org.uk/guidance/cg178. Accessed July 29, 2022.
    1. Remington G, Addington D, Honer W, et al. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry. 2017;62:604–616. doi: 10.1177/0706743717720448 - DOI - PMC - PubMed
    1. Japanese Society of Neuropsychopharmacology. Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”. Neuropsychopharmacol Rep. 2021;41:266–324. doi: 10.1002/npr2.12193 - DOI - PMC - PubMed